The Office of Science and Technology Policy released its National Security Science and Technology Strategy on 19 August 2026. The appendix updates the US Critical and Emerging Technologies (CET) list, narrowing it from 18 domains in 2024 to 14 in 2026. Brain-computer interfaces were reorganised in the process. The stand-alone “Human-Machine Interfaces” category from the 2024 list was retired. BCIs did not disappear from the CET list. They were moved into the “Future Computing Technologies” category, alongside advanced spatial computing, tactical edge computing, and photonic and neuromorphic computing. Neurotechnologies were separately moved into the “Biotechnology” category.
What the CET list actually does
The CET list is a policy-signalling instrument, not itself a binding regulation. It informs US federal research investment priority, procurement, and inter-agency coordination on export controls and investment screening. A designation as “critical” is a signal that federal enforcement, funding, and diplomatic attention will concentrate on the category. It is not a prohibition or a licence requirement in its own right.
What was removed from the CET list in 2026: data centres and data storage, batteries (the “Clean Energy Generation and Storage” category was replaced with the narrower “Nuclear Energy”), augmented reality, and standalone Advanced Gas Turbine Engines. What was added or elevated: post-quantum cryptography, integrated photonics, and high entropy alloys.
Reading the reorganisation as a demotion for BCIs would be a mistake. The 2026 list moves BCIs into the same tier as post-quantum cryptography, neuromorphic computing, and integrated photonics. It integrates BCI into the frontier-compute policy stack rather than treating it as a standalone human-interface curiosity.
The enforcement layer is already running, without a BCI-specific rule
While the CET list signals priority, the working export-control apparatus for BCI-adjacent equipment already exists inside the Entity List and dual-use catch-all controls. In August 2026 the Bureau of Industry and Security (BIS) settled a case against Plexon Inc., a Dallas-based neuroscience research equipment manufacturer. Plexon accepted a $1.7 million civil penalty, suspended, for unlicensed exports to Entity-Listed parties in China. Sandler Travis & Rosenberg’s trade-law coverage of the same case ties the destination to Chinese brain-control weaponry research; the specific entity name should be read from the BIS charging letter before being cited elsewhere.
Plexon manufactures multichannel neural recording and analysis systems used in neuroscience research. It is not itself a clinical BCI implant company. The enforcement matter is not against a clinical BCI operator, and it does not rest on any BCI-specific export rule. It rests on existing Entity List controls that apply to all US persons regardless of the underlying technology, and on dual-use catch-all provisions.
The 2021 BIS ANPRM never became a rule
In October 2021 the Bureau of Industry and Security published an Advance Notice of Proposed Rulemaking (ANPRM) inviting comment on whether brain-computer interfaces should be classified as emerging technology subject to specific export controls. The comment period closed in December 2021. As of 22 August 2026, no final rule specifically on BCI export controls has been published. The 2021 ANPRM remains the operative federal action naming BCIs as a candidate emerging-tech category for export control, and Entity List enforcement continues to do the actual work in the meantime.
The US posture, in the Issue 01 four-jurisdiction frame
Issue 01 of the Dargentic Intelligence Report classified the US regulatory posture on BCIs as State-Patchwork, driven by consumer neural-data legislation enacted by Colorado (2024), California (SB 1223 effective 2025; AB 1883 and AB 1542 in the current legislative session), Montana (2025), Connecticut (SB 1295 in force July 2026), and Vermont (H.814 and S.71 signed 2026), with further bills tracked in Alabama, Illinois, New York and Virginia.
The August 2026 federal activity does not overturn that State-Patchwork picture at the consumer neural-data layer. What it adds is a second US posture operating at a different point in the value chain: federal critical-tech designation plus Entity List export enforcement plus DARPA neurotechnology programme investment (SHINE and Firefox Special Notices, both August 2026). The federal industrial and export posture is closer in shape to the Industrial Builder posture that China and South Korea operate, than to the State-Patchwork posture the US operates at the consumer neural-data layer.
Two US postures now operate on the same technology at different stages of the value chain. Federal industrial and export policy at the input, capital and enforcement layer; state consumer-data policy at the deployment and consumer-facing layer. Cross-border operators building or selling BCI systems into or through the US need to track both.
What to watch
Whether BIS elevates the 2021 BCI ANPRM to a proposed rule or a final rule within the 2026-2027 window. Five years without a follow-up is a long dwell for an active ANPRM. Any BIS move on this in the coming quarters would materially change the export-control picture for BCI equipment manufacturers, not only research-equipment suppliers.
Whether the OSTP 2026 CET reorganisation translates into elevated federal R&D funding lines for BCI within the “Future Computing” bucket. DARPA’s SHINE and Firefox Special Notices in August 2026 are the near-term signal; further BTO, DSO, or Defense Advanced Research Projects Agency-adjacent announcements over the next six months will indicate whether the CET reclassification is being followed by budgetary weight.
Whether further BIS enforcement actions against US neuroscience-adjacent equipment manufacturers appear in the coming months. Plexon is one case. A pattern of two or three enforcement actions in the same window would indicate BIS has moved from occasional-enforcement to programmatic focus on the BCI-adjacent supply chain, without needing a new BCI-specific rule to do so.